博瑞医药董事长袁建栋表示："BGM0504注射液是一项重大创新成果。公司期待借助华润三九强大的注 册申报、市场覆盖和商业化能力，高效转化创新成果，让BGM0504注射液早日惠及中国患者。同时， 双方还将在临床研究策略上进行紧密协作，共同设计探索前沿的临床试验方案，为未来的学术推广奠定 坚实基础。这种优势互补、资源共享的合作模式，将有望推动实现双方共赢，并最终造福患者。" 华润三九董事长邱华伟表示："此次合作是双方优势的深度融合。华润三九的产业资源、商业化能力与 博瑞医药的研发优势、创新实力形成互补，既有利于加速BGM0504注射液的研发进程，也有利于推动 创新药管线的商业化落地，实现创新成果向临床价值的高效转化，达成创新驱动与商业拓展的协同发 展。双方将聚焦减重和降糖这两大核心功效构建品牌优势，同时积极拓展其他适应症市场，让这款创新 药的价值得到更充分的释放。" 当前，2型糖尿病（T2DM）和肥胖症已成为全球及中国面临的重大公共卫生挑战。国际糖尿病联盟 （IDF）第11版《世界糖尿病地图》显示，2024年我国糖尿病患者约1.48亿人。其中，T2DM患者在糖 尿病患者群体中占绝大多数，其患病率持续攀升；此外，超 ...

Group 1 - The core viewpoint of the news is the collaboration between China Resources Sanjiu (华润三九) and Borui Pharmaceutical (博瑞医药) to develop the BGM0504 injection, aimed at addressing the rising public health challenges of Type 2 Diabetes Mellitus (T2DM) and obesity in China [1][2] - The BGM0504 injection is a dual agonist of GLP-1 and GIP receptors, classified as an innovative peptide drug, and is currently in the critical phase of Phase III clinical trials [2] - The partnership aims to leverage the strengths of both companies, combining China Resources Sanjiu's commercial capabilities with Borui Pharmaceutical's research advantages to accelerate the development and commercialization of BGM0504 in the Chinese market [2] Group 2 - The collaboration is expected to enhance the brand's competitive edge by focusing on weight loss and blood sugar reduction, while also exploring other potential indications for the drug [2] - Both companies emphasize the importance of addressing unmet clinical needs and aim to efficiently translate innovative results into clinical value for patients [2] - The cooperative model of resource sharing and complementary advantages is anticipated to lead to mutual benefits for both companies and ultimately benefit patients [2]

Group 1 - Yabont Chemical signed a 10-year supply strategic agreement with Jiangsu Hengrui Medicine to enhance collaboration in the pharmaceutical supply chain, effective from August 1, 2025 [1] - Wei Hua New Materials plans to acquire controlling interest in Jiangsu Heyutai Chemical to extend its product chain and improve competitiveness, currently in the planning stage [2] - Fujirey received a government subsidy of 2.0074 million yuan, expected to positively impact profits in 2025 [4] Group 2 - Hangzhou Garden won the land use rights for a plot in Yuhang District for 130 million yuan, planning to build a smart ecological design R&D headquarters with a total investment of no more than 450 million yuan [5] - Baotai's clinical trial for BAT5906, a recombinant anti-VEGF monoclonal antibody, received approval for new indications, aiming to accelerate commercialization [6] - Weisheng Information won multiple projects with a total bid amount of 110 million yuan, including significant contracts with Southern Power Grid and State Grid [8] Group 3 - Dong'an Power reported a 27.37% year-on-year increase in engine sales for July, totaling 34,500 units [13] - Hanma Technology's truck sales reached 956 units in July, marking a 42.69% year-on-year increase [14] - Jiangsu Bank's executives received regulatory approval for their positions, effective immediately [15] Group 4 - Chip Origin expects Q2 revenue of 584 million yuan, a 49.90% increase quarter-on-quarter, with significant growth in intellectual property licensing fees [24] - Dream Network Technology plans to establish a high-end equipment industry investment fund with a target fundraising of 2 billion yuan [26] - Hefei Urban Construction and China Real Estate Development won land use rights for a residential plot in Hefei for 980 million yuan [28] Group 5 - Lu Kang Pharmaceutical's subsidiary received a drug registration certificate for a new medication for erectile dysfunction [28] - Lifan Pharmaceutical's Mesalazine enteric-coated tablets received a drug registration certificate for treating ulcerative colitis [29] - Yahu Pharmaceutical's APL-1401 clinical trial for ulcerative colitis showed positive preliminary results [30]

《合作研发协议》明确了博瑞医药将与华润三九在合作区域内就BGM0504注射液共同进行后续开发， 共同推进商业化。与此同时博瑞医药将作为BGM0504注射液在合作区域内的唯一上市许可持有人，承 担法律法规规定的应由MAH承担的全部义务和责任。 当前，2型糖尿病（T2DM）和肥胖症已成为全球及中国面临的重大公共卫生挑战。国际糖尿病联盟 （IDF）第11版《世界糖尿病地图》显示，2024年我国糖尿病患者约1.48亿人。其中，T2DM患者在糖 尿病患者群体中占绝大多数，其患病率持续攀升；此外，超重和肥胖作为慢性疾病中的独立病种及多种 慢性疾病的重要致病因素，在我国人群中的患病率呈持续上升趋势，亟需更多创新疗法以满足日益增长 的临床需求。 BGM0504注射液是一款GLP-1（胰高血糖素样肽1）和GIP（葡萄糖依赖性促胰岛素多肽）受体双重激 动剂，属于化学药品1类创新药，拟用于治疗T2DM和肥胖症。其独特的机制有望克服现有药物的部分 不足，为患者提供更有效、更安全、更便捷的治疗选择。目前，该药物已进展至III期临床试验关键阶 段。此次与华润三九的合作将有利于加速BGM0504注射液在中国市场的研发与上市步伐。 2025 ...

Core Viewpoint - The collaboration between Borui Pharmaceutical and China Resources Sanjiu focuses on the development, registration, production, and commercialization of BGM0504 injection in mainland China, highlighting the potential of this innovative drug in treating various metabolic diseases [1] Group 1: Collaboration Details - Borui Pharmaceutical and its subsidiaries have signed a cooperation research agreement with China Resources Sanjiu for the exclusive development and commercialization of BGM0504 injection [1] - The agreement grants China Resources Sanjiu a non-transferable exclusive license for development and commercialization, specifically for collaboration with Borui Pharmaceutical and its affiliates [1] Group 2: Product Information - BGM0504 injection is a dual agonist of GLP-1 and GIP, classified as a first-class innovative chemical drug that has not yet been marketed domestically or internationally [1] - The drug aims to activate downstream pathways of GIP and GLP-1, demonstrating potential biological effects such as blood sugar control, weight loss, and treatment of non-alcoholic steatohepatitis (NASH) [1] Group 3: Development Status - Currently, BGM0504 injection is still in the research and development phase, requiring the completion of Phase III clinical trials and approval from the National Medical Products Administration before it can be produced and marketed [1]

Core Viewpoint - The company, Borui Pharmaceutical, has signed a collaboration research agreement with China Resources Sanjiu for the development, registration, production, and commercialization of BGM0504 injection in mainland China [1] Group 1: Collaboration Agreement - Borui Pharmaceutical and its subsidiaries have granted China Resources Sanjiu exclusive collaboration development and commercialization licenses for BGM0504 injection [1] - The agreement allows for a sublicensable exclusive collaboration development implementation license and a sublicensable exclusive commercialization implementation license [1] Group 2: Product Details - BGM0504 injection is a dual agonist of GLP-1 and GIP, classified as a first-class innovative chemical drug that has not yet been marketed domestically or internationally [1] - The injection aims to control blood sugar, promote weight loss, and treat non-alcoholic steatohepatitis (NASH), showcasing potential for various metabolic disease treatments [1] Group 3: Development Status - BGM0504 injection is currently in the research phase and requires completion of Phase III clinical trials before it can be reviewed and approved by the National Medical Products Administration for production and market launch [1]

格隆汇8月1日丨博瑞医药（维权）(688166.SH)公布，公司及全资子公司博瑞制药(苏州)有限公司(以下 简称"博瑞制药")、博瑞新创生物医药科技(无锡)有限公司(该三家许可方统称为"博瑞医药及关联公司") 与华润三九医药股份有限公司(以下简称"华润三九")签署了《合作研发协议》，就BGM0504注射液在中 国大陆地区(不包含香港、澳门及台湾地区)的研发、注册、生产及商业化达成合作，博瑞医药及关联公 司授予华润三九一项仅与博瑞医药及关联公司合作的可分许可的排他性合作开发实施许可及一项可分许 可的独占性商业化实施许可。 ...

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the A-share listed companies, 1,144 secretaries earned over 1 million yuan annually, accounting for over 21% [1] - The age distribution of secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] Group 2 - The educational background of secretaries indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] - Only three secretaries hold a doctoral degree, specifically from Yiling Pharmaceutical, Kunming Pharmaceutical Group, and Jinhua Co., Ltd. [3] Group 3 - The average annual salary of secretaries in A-share listed Chinese medicine companies is 742,400 yuan, with 39% earning below 500,000 yuan, 42% earning between 500,000 and 1 million yuan, and 15% earning between 1 million and 2 million yuan [5] - The top five highest-paid secretaries are from China Resources Sanjiu, Jichuan Pharmaceutical, Tianjin Pharmaceutical, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries ranging from 1.3935 million to 2.5587 million yuan [7] Group 4 - There is significant variation in the number of investor receptions among listed companies, with 59% receiving fewer than 10 times a year, while 3% received between 300 and 1,000 times [9] - The five companies with the highest number of investor receptions are Zoli Pharmaceutical, Qizheng Pharmaceutical, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with receptions ranging from 207 to 410 times [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (27 individuals, 39%), between 500,000-1,000,000 yuan (29 individuals, 42%), between 1,000,000-2,000,000 yuan (10 individuals, 15%), between 2,000,000-3,000,000 yuan (2 individuals, 3%), and above 3,000,000 yuan (1 individual, 1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - In terms of educational qualifications, 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earners and Investor Relations - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu (2.5587 million yuan) - Cao Wei from Jichuan Pharmaceutical (2.4107 million yuan) - Yu Jie from Tian Shi Li (2.525 million yuan) - Wu Rui from Yiling Pharmaceutical (1.89 million yuan) - Jiang Xianhong from Yibai Pharmaceutical (1.3935 million yuan) [7] - The frequency of investor meetings varies significantly among companies, with 41 companies hosting fewer than 10 meetings annually (59%), 17 companies holding 10-100 meetings (25%), 9 companies conducting 100-300 meetings (13%), and 2 companies having 300-1000 meetings (3%) [7] Most Active Companies in Investor Relations - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical (410 meetings) - Qizheng Tibetan Medicine (404 meetings) - Yunnan Baiyao (298 meetings) - Jinghua Pharmaceutical (221 meetings) - Pian Zai Huang (207 meetings) [9]

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the A-share listed companies, 1,144 secretaries earned over 1 million yuan annually, accounting for over 21% [1] - The age distribution of secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] Group 2 - The educational background of secretaries indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's or higher [3] - Only three secretaries hold a doctoral degree, specifically from Yiling Pharmaceutical, Kunming Pharmaceutical Group, and Jinhua Co., Ltd. [3] Group 3 - The average annual salary of secretaries in A-share listed Chinese medicine companies is 742,400 yuan, with 39% earning below 500,000 yuan, 42% earning between 500,000-1 million yuan, 15% between 1-2 million yuan, 3% between 2-3 million yuan, and 1% above 3 million yuan [5] - The top five highest-paid secretaries are from China Resources Sanjiu, Jichuan Pharmaceutical, Tianjin Tasly, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries of 2.5587 million yuan, 2.4107 million yuan, 2.525 million yuan, 1.89 million yuan, and 1.3935 million yuan respectively [7] Group 4 - There is significant variation in the number of investor receptions among listed companies, with 59% receiving fewer than 10 times a year, 25% between 10-100 times, 13% between 100-300 times, and 3% between 300-1000 times [9] - The five companies with the highest number of investor receptions are Zoli Pharmaceutical, Qizheng Tibetan Medicine, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with receptions of 410, 404, 298, 221, and 207 respectively [9]